Rhenman & Partners Asset Management AB decreased its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 65.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 112,741 shares of the company’s stock after selling 217,894 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Pliant Therapeutics were worth $2,042,000 […]
Rhenman & Partners Asset Management AB cut its holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 65.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 112,741 shares of the company’s stock after selling 217,894 shares during the period. Rhenman […]
Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has received a consensus recommendation of “Buy” from the nine ratings firms that are currently covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have issued a report on the stock in […]
HC Wainwright restated their buy rating on shares of Pliant Therapeutics (NASDAQ:PLRX – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. The firm currently has a $36.00 target price on the stock. A number of other equities analysts also recently weighed in on the stock. Oppenheimer boosted their price […]
HC Wainwright restated their buy rating on shares of Pliant Therapeutics (NASDAQ:PLRX – Free Report) in a research note published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $36.00 target price on the stock. Other equities research analysts also recently issued research reports about the company. Royal Bank of Canada cut their price […]